S&P Futures
4,383.00-28.75(-0.65%)Dow Futures
34,903.00-71.00(-0.20%)Nasdaq Futures
14,862.50-175.25(-1.17%)Russell 2000 Futures
2,227.40-10.10(-0.45%)Crude Oil
73.25-0.37(-0.50%)Gold
1,832.50-3.30(-0.18%)
Moleculin Biotech, Inc. (MBRX)
After hours: 07:16PM EDT
Chart Events
Performance Outlook
| Previous Close | 3.1900 |
| Open | 3.1800 |
| Bid | 3.1700 x 900 |
| Ask | 3.2100 x 1000 |
| Day's Range | 3.1700 - 3.2400 |
| 52 Week Range | 3.1200 - 8.7800 |
| Volume | 103,297 |
| Avg. Volume | 280,880 |
| Market Cap | 91.307M |
| Beta (5Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5580 |
| Earnings Date | Aug 10, 2021 - Aug 16, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.33 |
- PR Newswire
Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received approval from the Bioethics Committee of the Medical University of Karol Marcinkiewicz in Poznań (Ethics Committee) as well as an allowance from the Polish Department of Registration of Medicinal Products (URPL) for a protocol amendment for its Phase 1/2 evaluat
- ACCESSWIRE
CO2 GRO Inc. Announces a CAD $65,500 Commercial Installation Agreement with a Canadian Licensed Producer
TORONTO, ON / ACCESSWIRE / June 22, 2021 / Toronto-based CO2 GRO Inc. ("GROW") (TSXV:GROW)(OTCQB:BLONF)(FSE:4021) is excited to announce that it has agreed to a commercial installation of its CO2 Delivery Solutions™ with a Canadian Licensed Producer ("LP or Customer") for the amount of CAD $65,500.
- PR Newswire
Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has commenced enrollment and dosed the first subject in its U.S. Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.
